Pharmacogenetics of bone treatments: The VDR and ERα gene story

Pharmacogenomics

Volumn 9, Issue 6, 2008, Pages 733-746

  Massart, Francesco ^a   Marcucci, Gemma ^b   Brandt, Maria Luisa ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Estrogen receptors; Gene polymorphism; Osteoporosis genetics; Pharmacogenomics; Treatment outcome; Vitamin D receptor

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ETIDRONIC ACID; MESSENGER RNA; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO; POLYADENYLIC ACID; RALOXIFENE; TRANSCRIPTION FACTOR CDX2; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALLELE; ASIAN; AUSTRALIA; BONE DENSITY; BONE MASS; BONE TURNOVER; CAUCASIAN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; ETHNIC DIFFERENCE; FEMALE; FRAGILITY FRACTURE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HORMONE SUBSTITUTION; HUMAN; LINKAGE ANALYSIS; MONOTHERAPY; MORBIDITY; NEGRO; NUCLEOTIDE REPEAT; OSTEOPOROSIS; PHARMACOGENETICS; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; ETHNOLOGY; GENETICS; METABOLISM; RACE;

ANIMALS; CONTINENTAL POPULATION GROUPS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; OSTEOPOROSIS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 48949119313     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.6.733     Document Type: Review

References (97)

1. Cummings SR, Melton LJ: Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319), 1761-1767 (2002).
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 22(3), 165-175 (2007).
3. Chrischilles EA, Butler CD, Davis CS, Wallace RB: A model of lifetime osteoporosis impact. Arch. Intern. Med. 151(10), 2026-2032 (1991).
4. Gennari L, Brandi ML: Genetics of male osteoporosis. Calcif. Tissue Int. 69(4), 200-204 (2001).
5. Brandt ML: Management of post-menopausal osteoporosis: something new on the horizon? J. Endocrinol. Invest. 26(2), 170-173 (2003).
6. Massart F, Reginster JY, Brandt ML: Genetics of menopause-associated diseases. Maturitas 40(2), 103-116 (2001).
7. Morrison NA, Qi JC, Tokita A et al.: Prediction of bone density from vitamin D receptor alleles. Nature 367(6460), 284-287 (1994).
8. Haussler MR, Whitfield GK, Haussler CA et al.: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13(3), 325-349 (1998).
9. Nejentsev S, Godfrey L, Snook H et al.: Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum. Mol. Genet. 13(15), 1633-1639 (2004).
10. Fang Y, van Meurs JB, d'Alesio A et al.: Promoter and 3′-untranslated-region haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam Study. Am. J. Hum. Genet. 77(5), 807-823 (2005).
11. Gennari L, Becherini L, Falchetti A et al.: Genetics of osteoporosis: roler of steroid hormone receptor gene polymorphisms. J. Steroid Biochem. Mol. Biol. 81(1), 1-24 (2002).
12. Morrison NA, Yeoman R, Kelly PJ et al.: Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc. Natl Acad. Sci. USA 89(15), 6665-6669 (1992).
13. Carbonell Sala S, Brandt ML: 2006 update on genetic determinants of osteoporosis. J. Endocrinol. Invest. 30(6), 2-7 (2007).
14. Ralston SH: Genetic control of susceptibility to osteoporosis. J. Clin. Endocrinol. Metab. 87(6), 2460-2466 (2002).
15. Gong G, Stern HS, Cheng SC et al.: The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos. Int. 9(1), 55-64 (1999).
16. Zintzaras E, Rodopoulou P, Koukoulis CN: BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. Dis. Markers 22(5-6), 317-326 (2006).
17. Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J: Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J. Bone Miner. Res. 19(3), 419-428 (2004).
18. Thakkinstian A, D'Este C, Attia J: Haplotype analysis of VDR gene polymorphisms: a meta-analysis. Osteoporos. Int. 15(9), 729-734 (2004).
19. Fang Y, Rivadeneira F, van Meurs JB, Pols HA, Ioannidis JP, Uitterlinden AG: Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis. Bone 39(4), 938-945 (2006).
20. Matsuyama T, Ishii S, Tokita A et al.: Vitamin D receptor genotypes and bone mineral density. Lancet 345(8959), 1238-1239 (1995).
21. Hunter D, Major P, Arden N et al.: A randomized controlled trial of vitamin D supplementation on preventing postmenopausal bone loss and modifying bone metabolism using identical twin pairs. J. Bone Miner. Res. 15(11), 2276-2283 (2000).
22. Massart F: Human races and pharmacogenomics of effective bone treatments. Gynecol. Endocrinol. 20(1), 36-44 (2005).
23. Howard G, Nguyen T, Morrison N et al.: Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J. Clin. Endocrinol. Metab. 80(9), 2800-2805 (1995).
24. Howard G, Nguyen T, Morrison N et al.: Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. Notification of genotype corrections. J. Clin. Endocrinol. Metab. 83(3), 1043 (1998).
25. Graafmans WC, Lips P, Ooms ME et al.: The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J. Bone Miner. Res. 12(8), 1241-1245 (1997).
26. Uitterlinden AG, Fang Y, van Meurs JB: Genetics and biology of vitamin D receptor polymorphisms. Gene 338(2), 143-156 (2004).
27. Sachs AB: Messenger RNA degradation in eukaryotes. Cell 74(3), 413-421 (1993).
28. Beelman CA, Parker R: Degradation of mRNA in eukaryotes. Cell 81 (2), 179-183 (1995).
29. Gennari L, Becherini L, Masi L et al.: Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. J. Clin. Endocrinol. Metab. 83(3), 939-944 (1998).
30. Morrison NA, Tokita A, Cheng QJ et al.: Allelic variation in the vitamin D receptor gene: major haplotypes in Caucasians. Bone 16(4), S105 (1995).
31. Ingles SA, Ross RK, Yu MC et al.: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 89(2), 166-170 (1997).
32. Ingles SA, Haile RW, Henderson BE et al.: Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomarkers Prev. 6(2), 93-98 (1997).
33. Grundberg E, Brändström H, Ribom EL et al.: A poly adenosine repeat in the human vitamin D receptor gene is associated with bone mineral density in young Swedish women. Calcif. Tissue Int. 73(5), 455-462 (2003).
34. Whitfield GK, Remus LS, Jurutka PW et al.: Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell Endocrinol. 177(1-2), 145-159 (2001).
35. Mocharla H, Butch AW, Pappas AA et al.: Quantification of vitamin D receptor mRNA by competitive polymerase chain reaction in PBMC: lack of correspondence with common allelic variants. J. Bone Miner. Res. 12(5), 726-733 (1997).
36. Verbeck W, Gombart AF, Shiohara M et al.: Vitamin D receptor: no evidence for allele-specific mRNA stability in cells which are heterozygous for the Taq I restriction enzyme polymorphism. Biochem. Biophys. Res. Commun. 238(1), 77-80 (1997).
37. Carling T, Rastad J, Akerstrom G et al.: Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J. Clin. Endocrinol. Metab. 83(7), 2255-2259 (1998).
38. Arai H, Miyamoto K, Taketani Y et al.: A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12(6), 915-921 (1997).
39. Jurutka PW, Remus LS, Whitfield GK et al.: The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 14(3), 401-420 (2000).
40. Colin EM, Weel AE, Uitterlinden AG et al.: Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1. 25-dihydroxyvitamin D3. Clin. Endocrinol. 52(2), 211-216 (2000).
41. Yamamoto H, Miyamoto K, Li B et al.: The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J. Bone Miner. Res. 14(2), 240-247 (1999).
42. Arai H, Miyamoto KI, Yoshida M et al.: The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 16(7), 1256-1264 (2001).
43. Morita A, Iki M, Dohi Y et al.: Effects of the Cdx-2 polymorphism of the vitamin D receptor gene and lifestyle factors on bone mineral density in a representative sample of Japanese women: the Japanese Population-based Osteoporosis (JPOS) Study. Calcif. Tissue Int. 77(6), 339-347 (2005).
44. Fang Y, van Meurs JB. Bergink AP et al.: Cdx-2 polymorphism in the promoter region of the human vitamin D receptor gene determines susceptibility to fracture in the elderly. J. Bone Miner. Res. 18(9), 1632-1641 (2003).
45. Macdonald HM, McGuigan FE, Stewart A et al.: Large-scale population-based study. shows no evidence of association between common polymorphism of the VDR gene and BMD in British women. J. Bone Miner. Res. 21(1), 151-162 (2006)
46. Byrne IM, Flanagan L, Tenniswood MP et al.: Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 141(8), 2829-2836 (2000).
47. Swami S, Krishnan AV, Feldman D: 1α,25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin. Cancer Res. 6(8), 3371-3379 (2000).
48. Kinuta K, Tanaka H, Moriwake T et al.: Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 141(4), 1317-1324 (2000).
49. Willing M, Sowers M, Aron D et al.: Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J. Bone Miner. Res. 13(4), 695-705 (1998).
50. Zhang YY, Long JR, Liu PY et al.: Estrogen receptor α and vitamin D receptor gene polymorphisms and bone mineral density: association study of healthy pre- and postmenopausal Chinese women. Biochem. Biophys. Res. Commun. 308(4), 777-783 (2003).
51. Bagger YZ, Hassager C, Heegaard AM, Christiansen C: Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins. Climacteric 3(2), 84-91 (2000).
52. Deng HW, Li J, Li JL et al.: Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum. Genet. 103(5), 576-585 (1998).
53. Kurabayashi T, Matsushita H, Tomita M et al.: Association of vitamin D and estrogen receptor gene polymorphism with the effects of long-term hormone replacement therapy on bone mineral density. J. Bone Miner. Metab. 22(3). 241-247 (2004).
54. Giguere Y, Dodin S, Blanchet C et al.: The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J. Bone Miner. Res. 15(6), 1076-1084 (2000).
55. Tofteng CL, Jensen JE, Abrahamsen B et al.: Two polymorphisms in the vitamin D receptor gene - association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. J. Bone Miner. Res. 17(8), 1535-1544 (2002).
56. Marc J, Prezelj J, Komel R et al.: VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos. Int. 10(4), 303-306 (1999).
57. Palomba S, Orio F Jr, Russo T et al.: BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos. Int. 16(8), 943-952 (2005).
58. Palomba S. Numis FG, Mossetti G et al.: Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin. Endocrinol. 58(3), 365-371 (2003).
59. Palomba S, Numis FG, Mossetti G et al.: Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum. Reprod. 18(1), 192-198 (2003).
60. Kurabayashi T, Tomita M, Matsushita H et al.: Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am. J. Obstet. Gynecol. 180(5), 1115-1120 (1999).
61. Bone HG, Greenspan SL, McKeever C et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J. Clin. Endocrinol. Metab. 85(2), 720-726 (2000).
62. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87(3), 985-992 (2002).
63. Smith EP, Boyd J, Frank GR et al.: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331(16), 1056-1061 (1994).
64. Korach KS: Insights from the study of animals lacking functional estrogen receptor. Science 266(5190), 1524-1527 (1994).
65. Windahl SH, Vidal O, Andersson G et al.: Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERβ(-/-) mice. J. Clin. Invest. 104(7), 895-901 (1999).
66. Ponglikitmongkol M, Green S, Chambon P: Genomic organization of the human oestrogen receptor gene. EMBO J. 7(11), 3385-3388 (1988).
67. Ioannidis JP, Ralston SH, Bennett ST et al.: Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 292(17), 2105-2114 (2004).
68. Wang CL, Tang XY, Chen WQ et al.: Association of estrogen receptor α gene polymorphisms with bone mineral density in Chinese women: a meta-analysis. Osteoporos. Int. 18(3), 295-305 (2007).
69. Ioannidis JP, Stavrou I, Trikalinos TA et al.: Association of polymorphisms of the estrogen receptor α gene with bone mineral density and fracture risk in women: a meta-analysis. J. Bone Miner. Res. 17(11), 2048-2060 (2002).
70. Han KO, Moon IG, Kang YS et al.: Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J. Clin. Endocrinol. Metab. 82(4), 991-995 (1997).
71. Kobayashi N, Fujino T, Shirogane T et al.: Estrogen receptor α polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 41(3), 193-201 (2002).
72. Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P et al.: Oestrogen-receptor-α gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin. Endocrinol. 52(5), 581-585 (2000).
73. Rapuri PB, Gallagher JC, Knezetic JA et al.: Estrogen receptor α gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas 53(4), 371-379 (2006).
74. Heilberg IP, Hernandez E, Alonzo E et al.: Estrogen receptor ( ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren. Fail. 27(2), 155-161 (2005).
75. Salmen T, Heikkinen AM, Mahonen A et al.: Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J. Bone Miner. Res. 15(2), 315-321 (2000).
76. Salmen T, Heikkinen AM, Mahonen A et al.: The protective effect of hormone-replacement therapy on fracture risk is modulated by estrogen receptor α genotype in early postmenopausal women. J. Bone Miner. Res. 5(12), 2479-2486 (2000).
77. Herrington DM, Howard TD, Brosnihan KB et al.: Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105(16), 1879-1882 (2002).
78. Herrington DM, Howard TD, Hawkins GA et al.: Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N. Engl. J. Med. 346(13), 967-974 (2002).
79. Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandt ML: Estrogen receptor α and β polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 13(3), 451-461 (2006).
80. Schuit SC, Oei HH, Witteman JC et al.: Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA 291(24), 2969-2977 (2004).
81. Maruyama H, Toji H, Harrington CR et al.: Lack of an association of estrogen receptor α gene polymorphisms and transcriptional activity with Alzheimer disease. Arch Neurol. 57(2), 236-240 (2000).
82. Uehar M, Arai Y, Watanabe S et al.: Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors 12(1-4), 217-225 (2000).
83. Becherini L, Gennari L, Masi L et al.: Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor α gene and their relationship to bone mass variation in postmenopausal Italian women. Hum. Mol. Genet. 9(13), 2043-2050 (2000).
84. Langdahl BL, Lokke E, Carstens M et al.: A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. J. Bone Miner. Res. 15(11), 2222-2230 (2000).
85. Albagha OM, McGuigan FE, Reid DM et al.: Estrogen receptor α gene polymorphisms and bone mineral density: haplotype analysis in women from the United Kingdom. J. Bone Miner. Res. 16(1), 128-134 (2001).
86. Yim CH, Choi JT, Choi HA et al.: Association of estrogen receptor α gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy. J. Bone Miner. Metab. 23(5), 395-400 (2005).
87. Yoneda K, Tanji Y, Ikeda N et al.: Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett. 186(2), 223-230 (2002).
88. Sadewa HA, Miyabe Y, Nishio H et al.: No relationship exists between itai-itai disease and TA repeat polymorphisms of the estrogen receptor α gene. Arch. Toxicol. 76(8), 467-469 (2002).
89. Zhai Y, Zhou G, Deng G et al.: Estrogen receptor α polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 130(7), 2001-2009 (2006).
90. Kunnas TA, Lehtimaki T, Karhunen PJ et al.: Estrogen receptor genotype modulates myocardial perfusion in young men. J. Mol. Med. 82(12), 821-825 (2004).
91. Schuit SC, van Meurs JB, Bergink AP et al.: Height in pre- and postmenopausal women is influenced by estrogen receptor α gene polymorphisms. J. Clin. Endocrinol. Metab. 89(1), 303-309 (2004).
92. Riancho JA, Zarrabeitia MT, Valero C, Sanudo C, Mijares V, Gonzalez-Macias J: A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density. Eur. J. Endocrinol. 155(1), 53-59 (2006).
93. Ongphiphadhanakul B, Chanprasertyothin S, Payattikul P et al.: Association of a T262C transition in exon 1 of estrogen-receptor-α gene with skeletal responsiveness to estrogen in post-menopausal women. J. Endocrinol. Invest. 24(10), 749-755 (2001).
94. Kozak M: Initiation of translation in prokaryotes and eukaryotes. Gene 234(2), 187-208 (1999).
95. Afshar-Kharghan V, Li CQ, Khoshnevis-Asl M et al.: Kozak sequence polymorphism of the glycoprotein (GP) Ibα gene is a major determinant of the plasma membrane levels of the platelet GP Ib-IX-V complex. Blood 94(1), 186-191 (1999).
96. Massart F, Brandi ML: Genetics of postmenopausal complications. In: Advances in gynecological endocrinology. Genazzani AR, Petraglia F, Artini PG (Eds). Parthenon Publishing, Lancaster, UK, 211-224 (2000).
97. Carbonell Sala S, Martineti V, Crossino AM, Brandi ML: Genetics and pharmacogenetics of estrogen response. Expert Rev. Endocrinol. Metab. 2(4), 503-516 (2007).